ABSTRACT
In April, 2020, just months into the COVID-19 pandemic, an international group of public health researchers published three lessons learned from the HIV pandemic for the response to COVID-19, which were to: anticipate health inequalities, create an enabling environment to support behavioural change, and engage a multidisciplinary effort. We revisit these lessons in light of more than 2 years' experience with the COVID-19 pandemic. With specific examples, we detail how inequalities have played out within and between countries, highlight factors that support or impede the creation of enabling environments, and note ongoing issues with the scarcity of integrated science and health system approaches. We argue that to better apply lessons learned as the COVID-19 pandemic matures and other infectious disease outbreaks emerge, it will be imperative to create dialogue among polarised perspectives, identify shared priorities, and draw on multidisciplinary evidence.
Subject(s)
COVID-19 , HIV Infections , Humans , COVID-19/epidemiology , Pandemics/prevention & control , SARS-CoV-2 , HIV Infections/epidemiology , HIV Infections/prevention & control , Disease Outbreaks/prevention & controlABSTRACT
This meeting report describes the University of California's (UC) Cannabis Research Workshop on May 26-27, 2021, which was organized by the UC Office of the President (UCOP) in partnership with the University of California, Davis (UCD). The event was designed to explore ways to strengthen research collaborations within and between campuses, discuss federal and state regulations and scientific priorities, and provide updates on current or recent cannabis and cannabinoid research studies. Topical areas were highlighted in four breakout sessions, including: 1) agronomy and environmental impacts; 2) biomedicine and public health; 3) economics, law, public policy, and social science; and 4) administrative considerations for supporting university research on cannabis and cannabinoids.
Subject(s)
Cannabinoids , Cannabis , Hallucinogens , Analgesics , Cannabinoid Receptor Agonists , Cannabinoids/therapeutic use , HumansABSTRACT
We examine the challenges and barriers to quality mentoring for new investigators from underrepresented racial/ethnic groups and propose solutions for establishing a robust pipeline of early-career scientists who are well equipped to conduct research on disparities in HIV and mental health. In addition, we review contributions to this special supplement on mentoring and advocate a multilevel strategy that targets funding agencies, academic and research institutions, mentors, and mentees to enhance the diversity of the nation's scientific workforce and ensure that the public health system benefits from innovations derived from the optimal use of existing human capital.
Subject(s)
Career Choice , Education, Public Health Professional/statistics & numerical data , HIV Infections/prevention & control , Health Services Research/statistics & numerical data , Mental Disorders/prevention & control , Mental Health , Mentors/statistics & numerical data , Research Personnel/education , Ethnicity , HIV Infections/epidemiology , HIV Infections/ethnology , Humans , Mental Disorders/epidemiology , Mental Disorders/ethnology , Racial Groups , Research Personnel/supply & distribution , United States/epidemiologyABSTRACT
The National Institutes of Health (NIH/NIMH), the Centers for Disease Control and Prevention (CDC), and the HIV/AIDS Bureau of the Health Resources and Services Administration (HRSA) support the CDC's Serostatus Approach to Fighting the HIV Epidemic (SAFE; Janssen et al., 2001). One aim of the strategy is to help individuals living with HIV (and their partners) adopt and sustain HIV and STD risk reduction, treatment adherence, and effective strategies for coping with HIV/AIDS. Efficacious interventions are needed by community organizations and clinics that provide evidence-based services. To expedite translation from research to practice, we convened scientist-practitioners, HIV treatment and prevention providers, and community/consumer members. In this article, we include an overview of prevention trials with HIV-positive persons presented at the meeting, discuss strengths and limitations, recommendations for future research, and discuss sponsoring agencies' plans for advancing prevention tailored for persons living with HIV.
Subject(s)
HIV Infections/prevention & control , Health Promotion/organization & administration , Risk Reduction Behavior , Centers for Disease Control and Prevention, U.S. , Counseling , Forecasting , HIV Infections/transmission , Humans , National Institutes of Health (U.S.) , Patient Education as Topic , Sexually Transmitted Diseases, Viral/prevention & control , United States , United States Health Resources and Services AdministrationABSTRACT
We apply a social determinants of health model to examine the association of select social and structural influences on AIDS diagnosis rates among men who have sex with men (MSM) in the U.S. states. Secondary data for key social and structural variables were acquired and analyzed. Standard descriptive and inferential statistics were used to examine bivariate and multivariate associations of selected social and structural variables with estimated rate of Stage 3 HIV infection (AIDS) per 100,000 MSM in 2010. We found that living in states with a higher demographic density of lesbian, gay, bisexual, and transgender persons is independently associated with lower AIDS diagnosis rates among MSM. In addition, we found that greater income inequality and higher syphilis rates among men were associated with greater AIDS diagnosis rates among MSM, which may be attributable to state policy environments that underinvest in social goods that benefit population health, and to the fact that ulcerative sexually-transmitted infections increase biological risk of HIV transmission and acquisition. To end the epidemic in the U.S., it will be critical to identify and address state-level social and structural factors that may be associated with adverse HIV outcomes for MSM.
Subject(s)
HIV Infections/epidemiology , Homosexuality, Male , Risk Reduction Behavior , Social Determinants of Health , Social Environment , Adult , HIV Infections/prevention & control , HIV Infections/transmission , Health Status Disparities , Homosexuality, Male/statistics & numerical data , Humans , Male , Multivariate Analysis , Residence Characteristics , Risk Factors , Risk-Taking , Sexual Behavior , Sexually Transmitted Diseases/epidemiology , Socioeconomic Factors , United States/epidemiologyABSTRACT
PURPOSE OF REVIEW: This review explores the policy implications of findings from the HIV Prevention Trials Network (HPTN 052) treatment as prevention (TasP) study. RECENT FINDINGS: To date, the potential of antiretrovirals to prevent sexual transmission of HIV by infected persons has been grounded in observational cohort, ecological, mathematical modeling, and meta-analytic studies. HPTN 052 represents the first randomized controlled trial to test the secondary prevention benefit of HIV transmission using antiretroviral treatment in largely asymptomatic persons with high CD4 cell counts. SUMMARY: The US National HIV/AIDS Strategy has among its key goals the reduction of incident HIV infections, improved access to quality care and associated outcomes, and the reduction in HIV-associated health disparities and inequities. HPTN 052 demonstrates that providing TasP, in combination with other effective prevention strategies offers the promise of achieving these life-saving goals. But HPTN 052 also highlights the need for cautious optimism and underscores the importance of addressing current gaps in the HIV prevention, treatment, and care continuum in order for 'TasP' strategies to achieve their full potential. Among these are necessary improvements in the capacity to expand HIV testing, facilitate effective linkage and retention in care, and improve treatment initiation, maintenance, and virus suppression.
Subject(s)
Antiretroviral Therapy, Highly Active/methods , Disease Transmission, Infectious/prevention & control , HIV Infections/drug therapy , HIV Seropositivity/drug therapy , Health Policy , Randomized Controlled Trials as Topic , Anti-HIV Agents/therapeutic use , Delivery of Health Care/methods , Female , HIV Infections/prevention & control , HIV Infections/transmission , HIV Infections/virology , HIV Seropositivity/transmission , HIV Seropositivity/virology , Humans , Male , Sexual PartnersSubject(s)
Financing, Government/standards , HIV Infections/diagnosis , HIV Infections/therapy , United States Dept. of Health and Human Services/standards , Anti-Retroviral Agents/administration & dosage , Data Collection/standards , HIV Seropositivity , Health Services/statistics & numerical data , Housing , Humans , United States , Viral LoadABSTRACT
OBJECTIVES: This study investigated the impact of HIV voluntary counseling and testing (VCT) on reproduction planning among 1634 adults in 2 sub-Saharan countries. METHODS: Data were obtained from a multisite randomized controlled trial. RESULTS: At 6 months post-VCT, the women more likely to be pregnant were younger (odds ratio [OR] = 2.5; 95% confidence interval [CI] = 1.0, 6.5), not using contraceptives (OR = 0.1; 95% CI = 0.1, 0.3), and HIV infected (OR = 3.0; 95% CI = 1.3, 7.0). An interaction emerged linking pregnancy intention at baseline and HIV serostatus with pregnancy at follow-up (OR = 0.1; 95% CI =.0, 0.4) Partner pregnancy rates did not differ by HIV serostatus among men. CONCLUSIONS: HIV diagnosis may influence reproduction planning for women but not for men.